Acute renal failure complicates the management of such patients because the resultant inability to remove toxic metabolites and to correct acid-base and electrolyte abnormalities is frequently associated with fluid overload. This may lead to pulmonary oedema and hypoxia and also to an increase in peripheral interstitial water with consequent decreased tissue perfusion. 6 Adequate enteral or parenteral nutritional support then becomes difficult because of the risk of further exacerbating fluid overload.
In the past, the standard methods of renal replacement therapy in such patients have been either intermittent machine-driven haemodialysis (HD) or peritoneal dialysis (PD), both of which have significant disadvantages in this group of patients. More recently, a wide variety of continuous renal replacement therapies (CRRT) have been introduced, which involve an extra-corporeal blood circuit and some kind of haemofilter. Accepted for publication October 11, 1989 Such treatment modalities are particularly suitable as renal replacement therapy for seriously ill patients. They offer greater facility and flexibility in fluid management and also in the provision of adequate nutritional support, without recourse to the specialised facilities and expertise of a dialysis unit. This article seeks both to review the various variations on the theme ofCRRT and to offer clinical guidelines for their institution and management in the ICU. INDICA nONS FOR RENAL REPLACEMENT THERAPY The indications for the institution of renal replacement therapy in the presence of renal failure include fluid overload, acidosis, hyperkalaemia and hyperuraemia.
Overhydration may be treated conservatively by fluid restriction. However, in the presence of persistent oliguria or anuria, active fluid removal is necessary to alleviate such symptoms as pulmonary oedema as well as to create space for volume therapy such as parental nutrition.
Renal replacement techniques may also be of value in the management of conditions not directly related to renal failure. Clearance of drugs and toxins, control of body temperature and fluid removal in the presence of diureticresistant congestive cardiac failure are therapeutic aims for which renal replacement techniques may be useful. 7, 8 Anaesthesia and Intensil'e Care, Vo/. 18, No. I, Februar) ', 1990 ST ANDARD THERAPY Scribner and his colleagues were of the opinion as long ago as 1960 that a continuous mode of renal replacement might be preferable to frequent intermittent high-flow HD in the critically ill and went on to demonstrate its practical application. 9 However, in subsequent years intermittent HD became the standard method of treatment for renal failure in these patients. Haemodialysis has significant disadvantages within this patient group ( Table 1) . Principal among these is haemodynamic instability. 10 Possible explanations for this include decreased systemic vascular resistance, I I the effect of dialysate bath components,12 rapid volume shifts '3 and electrolyte disequilibrium. ' 4 Haemodialysis is also associated with hypoxaemia l5 . 16 and an increase in oxygen consumption. 17 These effects are particularly deleterious in patients who have existing cardiovascular instability. 17 Furthermore, hypotension associated with haemodialysis may have deleterious effects on the kidney itself. There is considerable evidence that fresh ischaemic lesions occur during the course of ARF treated with HDI8 and that the failed kidney is unable to auto regulate its blood flow. '9 The period of oliguria associated with acute renal failure may therefore be prolonged because of ischaemic damage associated with hypotension during conventional haemodialysis. Critically ill patients are often hypercatabolic and have increased energy and protein requirements.2.'7.20.21 Haemodialysis, therefore, needs to be performed with increased frequency in order to remove the waste products of metabolism. Furthermore, in an attempt to decrease the frequency ofHD there may be a tendency to restrict fluids and nutritional intake and thus exacerbate nutritional deficit. 4 The use of intermittent HD within the ICU requires the attendance of specially trained nursing staff, thereby causing additional strains on the resources of what are often hard-pressed chronic dialysis services.
An alternative to intermittent HD is peritoneal dialysis (PD). Although less efficient at the removal of waste products, PD may be better tolerated in the critically ill patient and is more efficient than HD at fluid removal. Despite frequent technical difficulties associated with its use, such as catheter blockage and leakage around the catheter insertion site, PD is a simple procedure and does not require the use of specialised equipment. However, despite being associated with greater cardiovascular stability when compared with intermittent haemodialysis,22 PD may be contraindicated or impossible to perform because of intraabdominal pathology such as infection or recent surgery. Furthermore, large volumes of intra-abdominal fluid may lead to splinting of the diaphragm, decreased functional residual capacity (FRC), hypoxia and less effective ventilation. 23 Peritoneal dialysis in patients with multi-organ failure is also associated with a high incidence of peritonitis.
Both intermittent HD and PD, therefore, have significant disadvantages and potentially deleterious side-effects when performed as renal replacement therapy in critically ill and unstable patients.
CONTINUOUS RENAL REPLACEMENT THERAPY Within the last decade, particularly with the advent of small, low-resistance haemofilters, continuous renal replacement therapy (CRRT) has evolved as an alternative to these standard treatment modalities and its use is now widespread. Ultrafiltration and dialysis combined as in CA VHD but performed with the use of a pump-assisted veno-venous extracorporeal circuit.
GENERAL PRINCIPLES
OF OPERA nON Common to all these forms of CRR T is an extracorporeal blood circuit (ECC) by means of which blood is passed through a lowresistance haemofilter. The circuit is usually anti-coagulated by the continuous infusion of heparin 25 ,26,28.35 into the arterial or afferent limb proximal to the filter. The filter acts as a semipermeable membrane across which the blood flowing through the circuit exerts a hydrostatic pressure. This results in the formation of an ultrafiltrate made up of water and unbound, small molecular weight solutes such as urea, creatinine and electrolytes to which the membrane offers little resistance. The more porous the membrane, the greater will be the filtration fraction (the volume of ultrafiltrate formed for a given blood flow) and the larger the molecular weight of the solutes which pass through itY The membrane offers proportionally greater resistance to larger molecules and these are removed to a lesser extent. Filters in common use will not allow the significant passage of substance of a molecular weight greater than 20,000 daltons so that proteins and cellular components of blood are retained. 28 ,36 Solute removal is related to the volume of ultrafiltrate formed. With increasing ultrafiltration rates it is necessary to maintain the patient's intravascular volume by means of the simultaneous infusion of fluid so as to avoid hypovolaemia and haemodynamic instability. 25, 26, 28 Blood flow through the filter is maintained in an arteriovenous circuit by the patient's arterial blood pressure. Alternatively, flow may be achieved by means of an external roller pump inserted into either an arteriovenous or a veno-venous ECC. 32 Kramer and his colleagues first proposed Continuous Arterio-Venous Haemofiltration (CA VH) in 1977 as a method of treating fluid overload in patients with oliguric acute renal failure, both for the removal of fluid and also thereby to create space for the administration of parenteral nutrition. 24 25 Finally, the effectiveness of CRRT, particularly since the recent introduction of CA VHD, is such that its use can obviate the need for conventional HD in critically ill patients. 29 ,34 The risks attendant on the transfer of such patients from one centre to another solely for the purpose of dialysis can therefore be avoided.
HAEMOFILTERS
The haemofilters used in CRR Tare necessarily of a small internal volume, of the order of 40 to 70 ml, with low flow-resistance charateristics. The small internal volume of the filter means that the overall volume of blood in the ECC can be kept to a minimum. This facilitates anticoagulation and decreases the incidence of clotting. Low filter resistance allows adequate blood flow even in nonpumpdriven arterio-venous circuits.
There are two haemofilter configurations in common use; hollow-fibre and flat-plate. The hollow-fibre haemofilters have semipermeable membranes arranged in parallel capillary fibres. Blood travels down the centre of the fibres and ultrafiltrate is formed by the hydrostatic pressure difference across the fibre wall. More recently, haemofilters of a flat-plate configuration have been introduced in which the membrane is arranged in overlapping sheets between which the blood flows. These filters are of similar internal volume and membrane surface area as those of the hollow-fibre variety but have the advantage of a lower resistance to flow.
The membranes within the haemofilter are either cellulose-based, such as cellulose acetate or Cuprophan, or else are completely synthetic such as those made of polyacrylonitrile. The latter substance has been found to provide superior solute and water clearances and is more biocompatible. 37 -41 SOLUTE CLEARANCE Solute transfer across the filter membrane during ultrafiltration occurs by a process of convection. Hydrostatic pressure generated by blood flow causes water to move across the membrane, 'dragging' solutes such as urea and creatinine with it. The process of ultrafiltration alone does not affect the concentration of electrolytes and other small solutes in the patient's blood. These substances are transferred across the membrane in direct proportion to the amount of water which is removed. Their concentration in the ultrafiltrate is therefore identical to that in the plasma and the overall concentration of these substances remains unchanged. 26 However, the intravenous replacement of ultrafiltrate with a balanced electrolyte solution, which does not contain urea or creatinine, allows the overall clearance of these and other solutes from the blood. 25 With exchange volumes of the order of 1"2-15 litres/day in CA VH as described by Kramer and others, a urea clearance of approximately 9-10 mllmin is achieved. 25 ,28,35,42 Patients in acute renal failure are known to be hypercatabolic and may become more so with the development of sepsis or multi-organ failure. 2 ,17,2o,21 Urea clearances of this order achieved by CA VH may be insufficient to control hyperuraemia and acidosis. One solution to this problem is to add intermittent treatment with conventional HD as necessary, a procedure known as continuous ultrafiltration plus intermittent haemodialysis (CUPID).2,4,43,44 Continuous ultrafiltration decreases the frequency with which HD need be performed and is capable of maintaining adequate control of the patient's fluid status. There is no need to remove water from the patient during HD and the large volume fluid shifts which contribute to haemodynamic instability during this procedure can be avoided.
Various refinements of CA VH have been described to increase its efficacy at solute clearance so as to provide complete renal replacement therapy without recourse to conventional HD. These are directed towards improving convective solute clearance by the production of increased volumes of ultrafiltrate. The ultrafiltration rate is affected by mean arterial pressure, blood flow within the ECC, transmembrane hydrostatic pressure (TMP), membrane characteristics and plasma protein concentration. 28 . 36 Blood flow within the ECC increases proportionally with increasing mean arterial pressure. Any drop in pressure between the patient and the filter is related to the internal diameter and length of the arterial limb ofthe circuit. At blood flows of between 90 mllmin and 250 mllmin ultrafiltration rate is flowdependent. This is a result of the fact that as blood flow increases there is a proportional increase in pre-filter pressure and therefore in TMP. Ultrafiltration rate increases directly with a rise in TMP. Blood flow rates of less than 90 mllmin have no appreciable affect on pre-filter pressure or on ultrafiltration rate. Blood flows of greater than 250 ml/min are not associated with increased ultrafiltration despite a continued rise in pre-filter pressure, Anaesthesia and Intensive Care. Vol. 18 . No. I. February. 1990 probably because the ultrafiltration rate becomes membrane surface area limited at higher blood flows. 28 The transmembrane hydrostatic pressure driving ultrafiltration is opposed by the oncotic pressure exerted by plasma proteins. The ultrafiltration rate is therefore reduced at higher plasma protein concentrations. As ultrafiltration occurs and plasma water is removed, the protein concentration and the haematocrit of the blood remaining in the filter both rise. This effect is more marked with higher filtration fractions. The resultant rise in oncotic pressure, particularly at the distal end of the filter, overcomes the hydrostatic pressure driving ultrafiltration such that the latter process ceases to occur. (A plasma protein concentration of 80 g/l exerts an oncotic pressure of 70 mmHg whereas hydrostatic pressure within the filter varies between 30 and 70 mmHgy8 There is also a concommitant increase in haematocrit and blood viscosity which predisposes to a lowering of flow through the filter. Kramer noted that there was an inverse relationship between haematocrit and ultrafiltration rate and stated that arterio-venous haemofiltration was limited to patients with a haematocrit lower than 45%. 25 In practice this does not present a problem, as most critically ill patients with renal failure have haematocrits of between 25% and 40%.
From these observations it is evident that ultrafiltration rate and thus convective solute clearance can be improved by techniques directed towards increasing blood flow through the extracorporeal circuit and by increasing hydrostatic pressure exerted across the membrane, while at the same time counteracting the effect of rising plasma protein concentration and haematocrit (the so-called protocrit).45
TECHNIQUES FOR ENHANCING ULTRAFILTRATION
Techniques described to achieve an increase in ultrafiltration rate include suction assist, predilution and the addition of a blood pump to either an arterio-venous or more commonly a veno-venous circuit.
Suction assist
The TMP can be increased by simply lowering the level of the collection vessel relative to the filter, thus generating a more negative pressure in the ultrafiltrate compartment. (Negative pressure = Height in cm X 0.74 mmHg.) The technique of suction assist, described by Kaplan and his colleagues,44 involves a further decrease in pressure in the ultrafiltrate compartment generated by means of the attachment of vacuum suction to the ultrafiltrate outlet port of the haemofilter. Using standard wall outlet suction of 200 mmHg the ultrafiltration rate can be increased by a mean of 92%. Kaplan also noted that suction assist increases effective filter life by a mean of 94% and overcomes changes in ultrafiltration rate secondary to fluctuations in the patient's mean arterial pressure. Filtration fraction increased in Kaplan's study from a mean of 14% to 42%. This resulted in a 41.3% rise in haematocrit in the blood leaving the filter in those patients treated with suction assist as compared with a 12.3% change without its use. This increase in haematocrit was not found to cause problems associated with increased viscosity or coagulability in the patients studied, although this may have been due in part to low haematocrits in the group as a whole.
Kaplan concluded that suction assist provided a simple, safe method of increasing ultrafiltration rate and also effective filter life, especially in patients with low ECC blood flows. 44 
Predilution
Following his study of the use of suction assist, Kaplan later described the technique of predilution in which replacement fluid is given into the ECC proximal to the filter rather than distal to itso-called postdilution. 38 This has the effect of negating the increase in haematocrit and in oncotic pressure occurring during ultrafiltrate formation. If isovolumetric replacement of ultrafiltrate occurs in this way then the plasma protein concentration and haematocrit of the blood entering and leaving the filter will be the same. Predilution was found to increase ultrafiltration by a mean of 22%. Furthermore, urea clearance increased by 18% from a mean of 10.6 mllmin to 12.5 mllmin. This improvement in urea clearance may be explained by the rapid movement of urea from erythrocytes into plasma. This process is estimated to occur within as little as six seconds. The amount of urea available for clearance from blood during ultrafiltration is therefore increased. 46 ,47 Predilution may also be expected to allow the more liberal use of suction assist because the deleterious effects of the latter are counteracted by predilution. Indeed, Kaplan found that when used in combination, the two techniques resulted in an increase in net urea clearance of 60% without the generation of prohibitively high protocrits. Predilution may also be expected to result in a potential prolongation of effective filter life by dilution of prefilter clotting factors and platelets. 43 Mechanical blood pumps An alternative method of generating increased flow in the ECC is to use a mechanical blood pump rather than the patient's arterial blood pressure to propel blood through the filter. The use of a pump results in higher extracorporeal blood flows of up to 200 ml/min and the production of large volumes of ultrafiltrate. This is most commonly performed using single or double-lumen venous catheters placed in the subclavian or femoral veins in a technique known as continuous veno-venous haemofiltration (CVVH). Single or double-headed external roller pumps are used. 32 ,48 In a single pump system the pump head is placed on the proximal limb of the circuit between the patient and the filter. If a double-pump system is used, the second pump head is placed on the distal limb of the circuit to propel blood simultaneously back into the patient.
The advantages and disadvantages of the addition of a blood pump to the ECC are summarised in Table 3 . Longer effective filter life results from the ability of the mechanical pump to overcome the increased resistance to flow through the filter as it begins to become blocked by the deposition of fibrin clots and platelets. However, whereas the pressure within an arterio-venous circuit is limited by arterial blood pressure, much greater pressures may be generated within the filter with the use of an external pump and there is a risk of membrane rupture.
Although the use of a blood pump guarantees adequate flow through the filter despite changes in the patient's haemodynamic status, the safety element of autoregulation of flow in an arterio-venous circuit is lost. If excessive ultrafiltration occurs with CA VH such that the patient becomes hypovolaemic despite fluid replacement, the resultant hypotension will serve to decrease ultrafiltrate formation and so maintain intravascular volume. This mechanism is lost with the use ofa mechanical pump.
PROBLEMS OF HIGH FLUX HAEMOFILTRA TION The techniques described above to increase ultrafiltration rate in CA VH and the addition of blood pumps to the circuit as in CVVH are all effective at increasing solute clearance. 42 ,44 Blood levels of urea and creatinine can be adequately controlled even in patients who are hypercatabolic without recourse to the use of intermitttent HD. However, by their very success at producing large volumes of ultrafiltrate, of the order of 20 to 40 litres in a 24-hour period, these enhanced forms of haemofiltration pose certain logistical problems in fluid management such that many of the advantages of CRR T as compared with conventional HD may be lost.
In order to maintain the patient's intravascular volume in the face of high ultrafiltration rates, a continuous infusion of replacement fluid is necessary. This must be constantly and accurately titrated against the volume of ultrafiltrate produced. With the high fluid associated with enhanced CA VH and CVVH, relatively small discrepancies (Table 4 ) through the ultrafiltrate compartment of the filter,in the opposite direction to blood flow, a concentration gradient is created across the membrane. In addition to convective transfer of solutes during ultrafiltration, solute movement occurs by diffusion down the concentration gradient between blood and dialysate. The dialysate infused into the filter is collected, together with ultrafiltrate formed as in CA VH, from the ultrafiltrate outlet of the filter. (Figure 2 ). The dialysate flow rate (15-30 mllmin) through what is now effectively a haemodialyser is considerably slower than blood flow (50-150 mllmin) thus allowing equilibration between plasma and dialysate within the filter and greatly increasing solute clearance. Sigler and his 0.5 1.5 Potassium Chloride is added to make a dialysate concentration of 4 mmol/l colleagues studied solute transport in CA VHD and found mean whole blood clearances of urea and creatinine of 25.3 and 24.1 mllmin respectively, which were independent of ultrafiltration rate. 50 Clearances of urea and creatinine with CA VHD are therefore considerably greater than that produced by high flux haemofiltration (of the order of 12 to 15 ml/min) and are achieved without the need to generate large volumes of ultrafiltrate. 29 ,5o Solute transfer is limited by dialysate flow rate rather than by ultrafiltration rate ( Figure  3) . Urea clearance increases rapidly with , increasing dialysate flow rate up to a dialysate flow of 50 mllmin. Any further rise in flow results in little further improvement in urea clearance because at dialysate flow rates of greater than 50 ml/min there is incomplete equilibration between plasma and dialysate within the filter. In clinical practice it is not necessary to increase the dialysate flow rate above 2 litres/hr (approximately 32 mllmin) to maintain adequate control of urea and creatinine in even the most catabolic patients. 34 ,49 A 2 litres/hr dialysate flow can be used initially to reduce the blood urea acutely after which it can be maintained at an acceptable level with a flow of 1 litre/hr. 34 Geronemus has compared urea clearances in CA VHD using various filters and found that the parallel-plate configuration AN69 polyacrylonitrile haemodialyser (HOSPAL 69S SCU/CA VHD) yielded superior clearance values (Table 5) . 49 The ultrafiltration rate is still largely The lower ultrafiltration rate necessary in CA VHD contributes to the haemodynamic stability of this form of CRRT. Precise titration of replacement fluid against ultrafiltration is less critical than in high flux CA VH because the volumes of ultrafiltrate generated are smaller. The technique is well tolerated even in unstable patients requiring inotropic support. 34 The need to maintain a high blood flow through the filter to provide adequate convective clearance is avoided with CA VHD and the technique is effective with an extra-corporeal flow of as little as 50 mllmin and systolic blood pressure of 80 mmHg. 34 ,49 Methods of enhancing ultrafiltration, such as predilution and suction assist, are not required for CA VHD. Indeed, Geronemus has found that predilution used in conjuction with CAVHD actually decreases urea clearance, presumably by decreasing the concentration gradient for urea across the membrane and reducing diffusive clearance. 49 Phosphate clearance in CA VHD was found by Sigler to average 21. 3 mllmin and intravenous phosphate supplementation may be necessary. Potassium loss depends on how much potassium is added to the dialysate. When dialysate potassium concentration is 3 to 5 mmolll, potassium loss was found to be 57 mmollday. The dextrose concentration of 1.5% results in a mean net uptake of glucose into the blood of over 150 glday equivalent to 616 kcallday and may necessitate an insulin infusion to control blood sugar levels, especially at higher dialysate flow rates. 49 Continuous arterio-venous haemodialysis therefore provides flexible control of fluid and uraemic status without the need to supplement treatment with intermittent conventional HD. Overall electrolyte status can be manipulated both by altering the composition of intravenous replacement fluid and by intravenous supplementation or alternatively, as in the case of potassium, by altering its concentration in the dialysate. Potassium chloride is commonly added to the dialysate in a concentration of 4 to 5 mmolll to prevent hypokalaemia from excessive potassium loss.29,34,49,50
Middle molecule clearance
Clinical observations of patients with chronic renal failure and uraemia have suggested that certain manifestations of the uraemic syndrome, including neuropathy, are caused by the retention of solutes larger than urea itself. This so-called 'middle molecule' hypothesis is based on comparisons of chronic PD and HD. In HD, clearances of small molecular weight solutes are relatively high. In PD, although small solute clearance is comparatively low, clearances of larger solutes, in the molecular weight range 500 to 5000 daltons, are similar to that with HD. Since both treatment modalities are similarly effective at controlling uraemic symptoms, it has been suggested that clearance of these middle molecules is of primary importance in treating uraemia. 51 . 55 Henderson and Colton have demonstrated that middle molecule clearance is greater with convective transport in ultrafiltration than with diffusion-based solute transport in dialysis. 56 It is possible, therefore, that the treatment of uraemia in the critically ill patient might be best effected by high flux haemofiltration rather than with CA VHD, in which the major component of solute clearance is diffusive.
There is no evidence that this is in fact the case. Furthermore, Geronemus and Schneider have examined middle molecule clearance in CA VHD and found that although solute clearance declines with increasing molecular weight, there is nevertheless substantial clearance of middle molecules. Indeed, clearance of middle and small molecules in the study appeared superior to that achieved by CA VH. 57 One explanation for this may be their use of the polyacrylonitrile AN69S membrane which is more permeable than cellulose-based membranes to the passage of middle molecular weight solutes. 58 FLUID REPLACEMENT IN CRR T Ultrafiltration results in the formation of a solution with essentially the same electrolyte composition as that ofplasma. 26 The patient's intravascular volume is maintained by the simultaneous intravenous administration of replacement fluid. Ringer's lactate solution has been widely used as replacement fluid. Kaplan advocated the use of acetate or bicarbonate to replace lactate as the buffer in replacement fluid in patients with severe shock or liver failure, who might be expected to metabolise lactate poorly. 26 Haemofiltration fluid specifically formulated for use in replacement is commercially available (Table 6) .
Although attention must be paid to the electrolyte composition of replacement fluid in CRRT, the patient's clinical requirements may dictate that fluids other than simple crystalloid solutions be used. Hyperalimentation solutions, blood and blood products may need to form part of the replacement.
By using solutions containing colloid substances such as albumen to replace what is a crystalloid ultrafiltrate, it may be possible to maintain the colloid osmotic pressure and so reduce tissue oedema. For example, a patient with generalised expansion of the interstitial space resulting in peripheral and pulmonary oedema will have an ultrafiltrate produced by CA VH of fluid of approximately the same composition as that in the interstitial space. Colloid osmotic particles such as albumen given as replacement fluid will facilitate the movement of water from the interstitium into the intravascular space, which will then be removed by ultrafiltration. A combination of ultrafiltration and colloid replacement may result in overall loss of water from the interstitium and resolution of tissue oedema.
DRUG THERAPY IN CRRT Consideration should be given to the likely contribution of CRR T to drug clearance in the critically ill. It is important to maintain plasma concentrations of drugs so as to provide effective pharmacological activity and to avoid toxicity.
CAVH
There are three factors which will affect the removal of a particular drug by convection; ultrafiltration rate, delivery of drug to the filter and the ultrafiltration properties of the drug.
Factors affecting ultrafiltration rate have already been discussed. Clearly, the amount of a drug removed to a significant degree by ultrafiltration will increase proportionally if large volumes of ultrafiltrate are produced.
The most important factor affecting the delivery of a drug to the filter is its volume of distribution (Vd). The larger its Vd, the less likely it is that significant amounts of the drug will be delivered to the filter. Drugs that are highly bound to circulating proteins are largely confined to the vascular space and usually have a small Vd. Furthermore, the protein-bound fraction of the drug will not be available for removal by transfer across the filter membrane.
The main factors which affect the ultrafiltration properties of a drug -the degree to which it is removed during ultrafiltration -are its molecular weight and sieving coefficient. Most drugs have a molecular weight of less than 5000 daltons and are therefore potentially available for transfer across the membrane. The sieving coefficient (S) of a drug or solute is a mathematical expression of its ability to permeate a membrane and is given by the concentration of the solute in the ultrafiltrate divided by its concentration in the plasma. A solute has an S of 1.0 if it passes freely through the filter and 0 if it is completely rejected. The clearance of a solute or drug is equivalent to S multiplied by the ultrafiltration rate.
There is limited data for the clearance of specific drugs available in the literature, but the theory of drug therapy and drug removal in CA VH have been outlined in recent reviews by Bickley59 and Golper. 60 These articles list published values for S for a number of drugs and also outline clinical guidelines for calculating adjustments to drug dosages in patients undergoing CA VH.
CAVHD
Drug clearance is by a combination of convection and diffusion. Sigler has stated that small solute clearance during CA VHD is equal to the sum of diffusive and convective clearance. 50 However, studies of high flux haemodiafiltration suggest that there may be convective impairment of diffusive clearance. 61 There has been little work published on drug clearance in CA VHD. An initial study of the clearance of ceftazidime in CA VHD suggests that drug removal with this technique is greater than that occurring in haemofiltration alone, but further studies are needed. 62 . 63 It is clearly advisable that plasma levels of drugs are monitored where possible in patients undergoing CRR T and these levels used to alter dose regimes accordingly. '. 1990 V ASCULAR ACCESS CRRT requires vascular access such that blood can be removed from the patient, either from an artery if the patient's own blood pressure is used to generate flow in the ECC or from a central vein if a blood pump is used. The blood which has passed through the filter is returned to the patient via a peripheral or central vein. In the absence of a pre-existing arterio-venous fistula, vascular access for an arterio-venous ECC is achieved either by means of femoral artery and vein catheters or alternatively via a Scribner shunt.
Femoral catheters
The use of femoral artery and vein catheters with an internal diameter of up to 3 mm and which can be inserted percutaneously using a Seldinger wire technique 64 has been advocated by several authors.24.27.29,42.44 Such catheters can be positioned quickly and are relatively simple to use, requiring no special skill for their insertion. They also provide higher blood flows than that possible with either Scribner shunts or arterio-venous fistulae. 28 However, there are significant disadvantages associated with their use, including an increased risk of infection, haemorrhage (either overt or concealed), arterio-venous fistula formation and ischaemia in the limb distal to the catheter. 48 Their use is contraindicated in patients with peripheral vascular disease or in cases of ARF complicating major vascular surgery because of the risk of limb ischaemia. Their very success in providing higher flow within the ECC may be a contributing factor in morbidity and mortality because accidental dislodgement or disconnection of the arterial catheter may result in severe and uncontrollable haemorrhage. 48 
Scribner shunts
Scribner shunts 9 are an alternative to the use of femoral artery and vein catheters and comprise vessel tips (Quinton Instrument Co.) with an internal diameter up to 2.8 mm inserted by means of a surgical cut-down into either the radial artery and a suitable forearm vein or alternatively into the posterior tibial artery and the long saphenous vein at the ankle. 4 . 26 ,44 The vessel tips are attached via flexible silicone rubber tubing tunnelled subcutaneously. Scribner shunts require a degree of surgical skill for their insertion a,nd are associated with a lower flow in the ECC (50 to 100 mllmin compared with 80 to 120 ml/min in femoral artery catheters at the same mean arterial pressure).28 They can be positioned under local anaesthetic in the ICU and the risks of haemorrhage, infection and limb ischaemia are less than with femoral catheters. The patients are more mobile which facilitates their nursing care and the vascular access site is more easily monitored. 34 They are to be preferred in patients with peripheral vascular disease in whom shunts placed in the forearm rather than at the ankle appear to be associated with better blood flows.
Subclavian/Femoral vein catheters
If blood flow in the ECC is achieved by means of a mechanical blood pump as in Continuous Veno-Venous Haemofiltration (CVVH), vascular access can be through venous catheters alone. These may be singleor double-lumen catheters (Vas-Cath Inc.) inserted percutaneously with a Seldinger wire technique. 64 ANTICOAGULATION Anticoagulation of the blood in the ECC is necessary to prevent rapid clotting of the haemofilter. This must be achieved without causing a level of systemic anticoagulation such that bleeding complications occur.
Anticoagulation for CRRT is most commonly achieved with a continuous infusion of heparin into the ECC proximal to the filter. Different dose regimens have been described for use in CRRT. A bolus dose of between 2000 and 5000 IU given systemically before initiation of CRRT, followed by a continuous infusion into the ECC of 10 IU/kg/hr (or between 500 and 1500 IU/hr) has been advocated by several authors. 4 ,20,25,27,34 Kramer found that an infusion of 10 IU/kg/hr in CA VH caused no significant change in the patient's partial thromboplastin time (PTT) or thromboplastin time but resulted in an elevation of these values in the ECC. 25 Kaplan described haemorrhagic episodes in six of fifteen patients undergoing CA VH receiving an average dose of 10 IU Ikg/ hr, but all had pre-existing elevations of their PTT and five had hepatic failure also, 26 Kaplan and others have noted that in patients with a pre-existing bleeding diathesis or with low platelet counts (less than 100,000lmm 3 ) and an elevated PTT, effective filter function can be maintained without anticoagulation. 26 Lauer titrated the heparin infusion rate against ECC blood flow such that the patient's PTT was elevated to a level of twice the control value and found no bleeding complications associated with this regimen. 28 In practice, the rate of heparin infusion may be altered so as to achieve anticoagulation of the ECC such that effective filter life is maintained without changing the patient's systemic coagulation values.
In patients with pre-existing coagulopathies which may be exacerbated by the use of heparin, an alternative method of anticoagulation may be used. Regional heparinisation with simultaneous infusion of protamine into the distallimb of the ECC has been advocated but accurate titration of heparin against protamine is difficult and there is a risk of rebound anticoagulation. 65 ,66 An effective alternative is the use of an infusion of prostacyclin into the ECC, either alone (6-12 ng/kg/min) or in combination with low-dose heparin (250 IU/hr of heparin with 2-3 ng/kg/min ofprostacyclin). 34 Prostacyclin, which has anti-platelet aggregation activity, has been associated with systemic hypotension and other side-effects such as '. 1990 nausea and abdominal pain. 67 However, its use as a means of anti-coagulation in CRRT in the doses described above has not been associated with these complications or with problems of systemic haemorrhage. 34 FILTER LIFE The effective life of the haemofilter is limited by the deposition of protein, platelets and fibrin in the fibres or plates of the haemofilter such that flow through the filter becomes obstructed and ultrafiltration ceases. Factors which either promote or prevent clotting of blood in the ECC and so affect filter life are listed in Table 7 .
Anticoagulation is a major determinant of effective filter life. Factors which decrease flow or increase blood viscosity in the ECC predispose to early clotting of the filter. 68 CA VHD has an advantage over CA VH in this regard. There is a rise in blood viscosity as plasma water is removed during ultrafiltration, although this effect is modified by the use of predilution. The superior solute removal achieved with CA VHD allows the use of lower ultrafiltration rates than with CA VH and such an increase in blood viscosity can be minimised. Furthermore, as heat is lost from blood passing through the ECC, viscosity increases. The infusion of warm dialysate through the filter in CA VHD may decrease heat loss from the blood and help maintain flow.
Membrane configuration may also influence filter life. Parallel-plate filters have a lower resistance to flow than hollow-fibre filters and may therefore last longer. With adequate anticoagulation and blood flow in the ECC, a mean effective filter life of 48 hours may be expected, but individual filters can last as long as three to five days.20.25.27.34 SUMMARY Continuous Renal Replacement Therapy has significant advantages over standard forms of intermittent therapy and is now arguably the treatment of choice in the management of acute renal failure in critically ill patients. The most striking of these advantages is the guarantee of cardiovascular stability in addition to providing great flexibility and facility in the control of fluid and electrolyte status, as well as creating space for parenteral nutrition. 4 Continuous renal replacement techniques can be performed at the bedside by nursing staff not specifically trained in dialysis and can provide adequate replacement of renal function without the use of expensive equipment and without recourse to the facili ties of a dialysis unit. 34 As a simple and safe procedure, it is well within the scope of small intensive care units in peripheral hospitals and can obviate the need to transport critically ill patients to larger centres specifically for dialysis treatment.
There are no studies to demonstrate that the use of CRRT rather than conventional dialysis improves overall mortality and this remains high. However, the facility and flexibility in patient management afforded by continuous renal replacement therapy as outlined above would appear to justify its use as the treatment of choice in the ICU setting. Furthermore, evidence that the provision of adequate nutritional support in critically ill patients with acute renal failure may improve outcome would recommend its use because of the unrestricted volumes of parenteral nutrition which can be safely administered to patients undergoing continuous renal replacement therapy. 2, 20, 21, 69 The choice of which form to use will be influenced by the experience, expertise and personal preference of the medical and nursing staff involved and also by the clinical situation and the resources available. The practical aspects of continuous renal replacement therapy are relatively simple to learn and are therefore easily introduced into units in which the need for renal replacement therapy is infrequent. Further studies are needed to elucidate the effects of continuous renal replacement therapy on the clearance of drugs, trace elements, amino acids 4 . 70 ,71 and other components of nutritional support and also to assess 10ng-terIl). effects on morbidity and mortality. However, it remains a safe simple and effective form of therapy in th~ management of renal insufficiency in the critically ill.assistance and expertise of our nursing colleagues who have ensured the successful development of these techniques when there were few guidelines available for their use.
